



## CPT<sup>®</sup> Category I Vaccine Codes

Codes 90655, 90656, 90657, 90658, 90685, 90686, 90687, 90688 have been redefined to reflect dosage amounts, in lieu of age indications. These code revisions are identified with strike-out and underline conventions. A CPT Assistant article was published in May 2016 and is included on the AMA CPT website to explain these revisions and provide instructions for reporting.

▲90655	Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, <del>when administered to children 6-35 months of age</del> <u>0.25 mL dosage</u> , for intramuscular use	Released July 1, 2016  Implementation January 1, 2017	CPT 2017
▲90656	Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, <del>when administered to individuals 3 years and older</del> <u>0.5 mL dosage</u> , for intramuscular use	Released July 1, 2016  Implementation January 1, 2017	CPT 2017
▲90657	Influenza virus vaccine, trivalent (IIV3), split virus, <del>when administered to children 6-35 months of age</del> <u>0.25 mL dosage</u> , for intramuscular use	Released July 1, 2016  Implementation January 1, 2017	CPT 2017

▲90658	Influenza virus vaccine, trivalent (IIV3), split virus, <del>when administered to individuals 3 years of age and older</del> <u>0.5 mL dosage</u> , for intramuscular use	Released July 1, 2016  Implementation January 1, 2017	CPT 2017
▲90685	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, <del>when administered to children 6-35 months of age</del> <u>0.25 mL dosage</u> , for intramuscular use	Released July 1, 2016  Implementation January 1, 2017	CPT 2017
▲90686	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, <del>when administered to individuals 3 years of age and older</del> <u>0.5 mL dosage</u> , for intramuscular use	Released July 1, 2016  Implementation January 1, 2017	CPT 2017

▲90687	Influenza virus vaccine, quadrivalent (IIV4), split virus, <del>when administered to children 6–35 months of age</del> <u>0.25 mL dosage</u> , for intramuscular use	Released July 1, 2016  Implementation January 1, 2017	CPT 2017
--------	--	---	----------

▲90688	Influenza virus vaccine, quadrivalent (IIV4), split virus, <del>when administered to individuals 3 years of age and older</del> <u>0.5 mL dosage</u> , for intramuscular use	Released July 1, 2016  Implementation January 1, 2017	CPT 2017
--------	--	---	----------

Code 90661 was accepted for revision to include the term “trivalent” and the dosage amount (0.5 mL) at the February 2016 CPT Editorial Panel meeting for electronic release on July 1, 2016, for implementation on January 1, 2017, and for inclusion in the 2017 CPT book.

▲90661	Influenza virus vaccine, <u>trivalent</u> (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, <u>0.5 mL dosage</u> , for intramuscular use	Released July 1, 2016  Implementation January 1, 2017	CPT 2017
--------	---	---	----------



Code 90674 was accepted at the February 2016 CPT Editorial Panel meeting for electronic release on July 1, 2016, for implementation on January 1, 2017, and for inclusion in the 2017 CPT book.

#●90674	Influenza virus vaccine, quadrivalent (ccIIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Released July 1, 2016  Implementation January 1, 2017	CPT 2017
---------	--	---	----------

Code 90682 was accepted at the May 2016 CPT Editorial Panel meeting for electronic release on July 1, 2016, for implementation on January 1, 2017 and inclusion in the 2018 CPT book.

↗●90682	Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use	Released July 1, 2016  Implementation January 1, 2017	CPT 2018
---------	--	---	----------

Code 90750 was accepted at the May 2016 CPT Editorial Panel meeting for electronic release on July 1, 2016, for implementation on January 1, 2017 and inclusion in the 2018 CPT book.

↗●90750	Zoster (shingles) vaccine (HZV), recombinant, sub-unit, adjuvanted, for intramuscular injection	Released July 1, 2016  Implementation January 1, 2017	CPT 2018
---------	---	---	----------



## FDA Approval Notifications

The FDA approval pending indicator  $\nearrow$  is removed from code 90653. The 2017 CPT code set publication will exclude the  $\nearrow$  FDA approval pending symbol.

90653	Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use	<b>FDA Approval</b> November 24, 2015	<b>Published in CPT 2013</b>
-------	--	--	------------------------------

The FDA approval pending indicator  $\nearrow$  is removed from code 90625. The 2017 CPT code set publication will exclude the  $\nearrow$  FDA approval pending symbol.

90625	Cholera vaccine, live, adult dosage, 1 dose schedule, for oral use	<b>FDA Approval</b> June 10, 2016	<b>Published in CPT 2016</b>
-------	--	--------------------------------------	------------------------------

## ACIP Standard Nomenclature Revisions

The revision of code 90734 was accepted at the October 2015 CPT Editorial Panel meeting for electronic release and 2017 CPT code set publication to include two US Vaccine abbreviations designated by the Advisory Committee on Immunization Practices (ACIP) as noted in underscore text below.

<b>▲</b> 90734	Meningococcal conjugate vaccine, serogroups A, C, Y and W-135, quadrivalent ( <u>MCV4</u> or <u>MenACWY</u> ), for intramuscular use	Released July 1, 2016  Implementation January 1, 2017	<b>CPT 2017</b>
----------------	--	---	-----------------

$\nearrow$  = FDA approval pending   ● = New code   ▲ = Revised code   # = Resequenced code